BioLab Holdings Commences Groundbreaking Clinical Trial
BioLab Holdings, Inc., a prominent medical manufacturer specializing in regenerative wound care, has launched a pivotal clinical trial that aims to innovate treatment methods for chronic wounds. This multicenter study will assess the effectiveness of four human placental membrane (HPM) products alongside standard care, compared to standard care alone, in treating nonhealing diabetic foot ulcers and venous leg ulcers.
Overview of the Clinical Trial
The clinical trial, titled "A Multicenter, Prospective, Randomized Controlled Modified Multi-Platform Trial Assessing the Efficacy of Human Placental Membrane Products and Standard of Care Versus Standard of Care Alone in the Management of Nonhealing Diabetic Foot Ulcers and Venous Leg Ulcers (BIOCAMP)," is set to enroll 650 participants across approximately 30 clinical sites. This extensive study exemplifies BioLab's dedication to enhancing clinical quality through precise research methodologies.
Significant Milestone for Wound Care
Dr. Marshall Medley, chief medical officer of BioLab Holdings, expressed enthusiasm about this milestone, stating, "This study represents a major milestone in our commitment to advancing wound care through rigorous clinical research. By evaluating our full suite of amnion-based products in a real-world setting, we aim to provide clinicians with robust data to guide treatment decisions for patients with chronic wounds." This proactive approach demonstrates that BioLab is truly committed to pushing the boundaries of medical science.
What Participants Can Expect
In the trial, participants will be randomized into groups to receive one of the four BioLab products—Tri-Membrane Wrap, Membrane Wrap, Membrane Wrap-Lite, or Membrane Wrap-Hydro—alongside standard treatment or standard treatment alone. All treatments will be administered weekly for a maximum of 12 weeks or until complete wound closure is confirmed, providing thorough and updated measures of healing efficacy.
Research Focus on Real-World Clinical Outcomes
One of the primary aims of the study is to document real-world clinical outcomes that will contribute to the growing body of evidence supporting the utilization of placental-derived allografts in chronic wound management. This research is significant as it endeavors to refine the approach clinicians take in wound care.
About BioLab Holdings
BioLab Holdings, Inc. stands as a leading manufacturer based in Phoenix, dedicated to modernizing wound healing and regenerative medicine. The company’s product offerings include Membrane Wrap Lite, Tri-Membrane Wrap, Membrane Wrap, and Membrane Wrap - Hydro, which are all derived from human amniotic membrane. These allografts are specifically designed to retain the natural properties of the tissues to enhance healing outcomes. BioLab's commitment to quality is unwavering, focused on delivering safe, high-quality products through innovation and exceptional customer service.
Contact Information
For further inquiries, you can reach out to Kwyn Lowe.
Phone: 406.314.5120
Email: [Contact Information Redacted]
Frequently Asked Questions
What is the primary objective of BioLab's clinical trial?
The trial aims to evaluate the effectiveness of BioLab's human placental membrane products in treating chronic wounds compared to standard care.
How many participants will the clinical trial involve?
The study plans to enroll 650 participants across up to 30 clinical sites.
What types of ulcers are being addressed in this study?
The trial focuses on nonhealing diabetic foot ulcers and venous leg ulcers.
What types of treatments are being evaluated in the trial?
The trial evaluates four different amnion-based therapies in addition to standard care.
Who is the chief medical officer of BioLab Holdings?
Dr. Marshall Medley serves as the chief medical officer at BioLab Holdings, Inc.
